Glomerular disease in pregnancy

Andrew Smyth, Vesna D Garovic

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple glomerular diseases may affect women of childbearing age. The relationship between glomerular disease and pregnancy is complex and should be approached from two major standpoints: the effects of pregnancy on maternal disease activity and progression and effects of the disease and related medical therapy on the developing fetus. Glomerular disease may be active or quiescent at conception, may flare during pregnancy, or may occur de novo during pregnancy. Adverse fetal outcomes (spontaneous abortion, prematurity, intrauterine growth retardation) and maternal outcomes (preeclampsia, renal disease flare) are common, particularly in patients with active disease and those with advanced renal insufficiency. Consequently, irrespective of the underlying etiology, remission of renal disease for >6 months prior to conception is recommended. The risk for progression is increased for patients with established renal insufficiency with creatinine values >1.4 mg/dL. The differential diagnosis of worsening proteinuria, which commonly occurs during the third trimester in all proteinuric renal diseases, should include renal disease flare and preeclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. If indicated, a renal biopsy can be safely performed prior to 32 weeks gestation in women with adequately controlled blood pressure and in the absence of coagulation abnormalities. The goal of therapy during pregnancy is control of disease activity, both renal and systemic, with medications that are relatively safe for a growing fetus. Consequently, the optimal management of these patients crosses specialties and should include a nephrologist, obstetrician, and, commonly, a rheumatologist.

Original languageEnglish (US)
Title of host publicationCore Concepts in Parenchymal Kidney Disease
PublisherSpringer New York
Pages315-328
Number of pages14
Volume9781461481669
ISBN (Print)9781461481669, 1461481651, 9781461481652
DOIs
StatePublished - Jul 1 2014

Fingerprint

Pregnancy
Kidney
Pre-Eclampsia
Proteinuria
Renal Insufficiency
Fetus
Mothers
Fetal Growth Retardation
Third Pregnancy Trimester
Spontaneous Abortion
Disease Progression
Creatinine
Differential Diagnosis
Blood Pressure
Hypertension
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Smyth, A., & Garovic, V. D. (2014). Glomerular disease in pregnancy. In Core Concepts in Parenchymal Kidney Disease (Vol. 9781461481669, pp. 315-328). Springer New York. https://doi.org/10.1007/978-1-4614-8166-9_22

Glomerular disease in pregnancy. / Smyth, Andrew; Garovic, Vesna D.

Core Concepts in Parenchymal Kidney Disease. Vol. 9781461481669 Springer New York, 2014. p. 315-328.

Research output: Chapter in Book/Report/Conference proceedingChapter

Smyth, A & Garovic, VD 2014, Glomerular disease in pregnancy. in Core Concepts in Parenchymal Kidney Disease. vol. 9781461481669, Springer New York, pp. 315-328. https://doi.org/10.1007/978-1-4614-8166-9_22
Smyth A, Garovic VD. Glomerular disease in pregnancy. In Core Concepts in Parenchymal Kidney Disease. Vol. 9781461481669. Springer New York. 2014. p. 315-328 https://doi.org/10.1007/978-1-4614-8166-9_22
Smyth, Andrew ; Garovic, Vesna D. / Glomerular disease in pregnancy. Core Concepts in Parenchymal Kidney Disease. Vol. 9781461481669 Springer New York, 2014. pp. 315-328
@inbook{1fac6d58c0c24e4690076575f06f61a5,
title = "Glomerular disease in pregnancy",
abstract = "Multiple glomerular diseases may affect women of childbearing age. The relationship between glomerular disease and pregnancy is complex and should be approached from two major standpoints: the effects of pregnancy on maternal disease activity and progression and effects of the disease and related medical therapy on the developing fetus. Glomerular disease may be active or quiescent at conception, may flare during pregnancy, or may occur de novo during pregnancy. Adverse fetal outcomes (spontaneous abortion, prematurity, intrauterine growth retardation) and maternal outcomes (preeclampsia, renal disease flare) are common, particularly in patients with active disease and those with advanced renal insufficiency. Consequently, irrespective of the underlying etiology, remission of renal disease for >6 months prior to conception is recommended. The risk for progression is increased for patients with established renal insufficiency with creatinine values >1.4 mg/dL. The differential diagnosis of worsening proteinuria, which commonly occurs during the third trimester in all proteinuric renal diseases, should include renal disease flare and preeclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. If indicated, a renal biopsy can be safely performed prior to 32 weeks gestation in women with adequately controlled blood pressure and in the absence of coagulation abnormalities. The goal of therapy during pregnancy is control of disease activity, both renal and systemic, with medications that are relatively safe for a growing fetus. Consequently, the optimal management of these patients crosses specialties and should include a nephrologist, obstetrician, and, commonly, a rheumatologist.",
author = "Andrew Smyth and Garovic, {Vesna D}",
year = "2014",
month = "7",
day = "1",
doi = "10.1007/978-1-4614-8166-9_22",
language = "English (US)",
isbn = "9781461481669",
volume = "9781461481669",
pages = "315--328",
booktitle = "Core Concepts in Parenchymal Kidney Disease",
publisher = "Springer New York",

}

TY - CHAP

T1 - Glomerular disease in pregnancy

AU - Smyth, Andrew

AU - Garovic, Vesna D

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Multiple glomerular diseases may affect women of childbearing age. The relationship between glomerular disease and pregnancy is complex and should be approached from two major standpoints: the effects of pregnancy on maternal disease activity and progression and effects of the disease and related medical therapy on the developing fetus. Glomerular disease may be active or quiescent at conception, may flare during pregnancy, or may occur de novo during pregnancy. Adverse fetal outcomes (spontaneous abortion, prematurity, intrauterine growth retardation) and maternal outcomes (preeclampsia, renal disease flare) are common, particularly in patients with active disease and those with advanced renal insufficiency. Consequently, irrespective of the underlying etiology, remission of renal disease for >6 months prior to conception is recommended. The risk for progression is increased for patients with established renal insufficiency with creatinine values >1.4 mg/dL. The differential diagnosis of worsening proteinuria, which commonly occurs during the third trimester in all proteinuric renal diseases, should include renal disease flare and preeclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. If indicated, a renal biopsy can be safely performed prior to 32 weeks gestation in women with adequately controlled blood pressure and in the absence of coagulation abnormalities. The goal of therapy during pregnancy is control of disease activity, both renal and systemic, with medications that are relatively safe for a growing fetus. Consequently, the optimal management of these patients crosses specialties and should include a nephrologist, obstetrician, and, commonly, a rheumatologist.

AB - Multiple glomerular diseases may affect women of childbearing age. The relationship between glomerular disease and pregnancy is complex and should be approached from two major standpoints: the effects of pregnancy on maternal disease activity and progression and effects of the disease and related medical therapy on the developing fetus. Glomerular disease may be active or quiescent at conception, may flare during pregnancy, or may occur de novo during pregnancy. Adverse fetal outcomes (spontaneous abortion, prematurity, intrauterine growth retardation) and maternal outcomes (preeclampsia, renal disease flare) are common, particularly in patients with active disease and those with advanced renal insufficiency. Consequently, irrespective of the underlying etiology, remission of renal disease for >6 months prior to conception is recommended. The risk for progression is increased for patients with established renal insufficiency with creatinine values >1.4 mg/dL. The differential diagnosis of worsening proteinuria, which commonly occurs during the third trimester in all proteinuric renal diseases, should include renal disease flare and preeclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. If indicated, a renal biopsy can be safely performed prior to 32 weeks gestation in women with adequately controlled blood pressure and in the absence of coagulation abnormalities. The goal of therapy during pregnancy is control of disease activity, both renal and systemic, with medications that are relatively safe for a growing fetus. Consequently, the optimal management of these patients crosses specialties and should include a nephrologist, obstetrician, and, commonly, a rheumatologist.

UR - http://www.scopus.com/inward/record.url?scp=84949178338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949178338&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8166-9_22

DO - 10.1007/978-1-4614-8166-9_22

M3 - Chapter

AN - SCOPUS:84949178338

SN - 9781461481669

SN - 1461481651

SN - 9781461481652

VL - 9781461481669

SP - 315

EP - 328

BT - Core Concepts in Parenchymal Kidney Disease

PB - Springer New York

ER -